Drug Profile
Research programme: phosphatidylinositol 3-kinase inhibitors - Oncalis/ChemDiv
Alternative Names: ONC-201Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ChemDiv; Oncalis
- Class
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 29 Oct 2008 Preclinical trials in Cancer in USA (PO)